Sophia Genetics SA（SOPH）の株式分析SOPHSophia Genetics SA

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide. It operates in the Healthcare sector.

SOPHiA Genetics (SOPH) is a good buy right now due to its strong revenue growth of 27% year-over-year in Q2 2026, with projected full-year revenue guidance raised to between $94 million and $96 million. Additionally, the stock has experienced a remarkable 74.30% year-to-date increase, reflecting strong investor confidence. The main risk is the negative earnings per share of -0.30 reported in Q2, which indicates ongoing financial challenges that investors should monitor closely.